Pharma Capital

Clinigen Group PLC boss excited about perampanel South Africa approval

Chief executive of Clinigen Group PLC (LON:CLIN) Shaun Chilton explains the significance of the firm's approval for perampanel, a treatment for seizures associated with epilepsy.
"This is the first new anti-epileptic to be approved in South Africa for quite a number of years," he told Proactive's Charlotte Kan, adding that epilepsy affects one in every 100 people in the country.

 

View full CLIN profile

Clinigen Group PLC Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.